CATALYSIS CAPITAL PARTNERS is pleased to announce that Sam Williams, PhD has joined CATALYSIS as a Senior Advisor. Sam Williams has over 10 years’ experience in investment banking focusing on biotechnology and pharmaceuticals, most recently at Lehman Brothers where he held the position of Industry Group Leader for European Pharmaceuticals and Chemicals. Sam Williams was ranked the number one European Biotechnology equity analyst by Institutional Investor magazine in 2004, 2005 and 2006 and by Thomson Extel in 2004 and 2005.
Prior to Lehman Brothers, he was Senior Biotechnology Research Analyst at Robertson Stephens International Limited. Sam Williams has a PhD from the Laboratory of Molecular Biology in Cambridge where he worked in the research group of Sir Gregory Winter FRS, scientific co-founder of Cambridge Antibody Technology (CAT) and Domantis. He has first-hand experience of the drug discovery process from his time as a Director of a private UK biotechnology company, Modern Biosciences. Sam Williams is also a non-Executive Director of two private UK biotechnology companies and is a Board member of the UK BioIndustry Association (BIA).
CATALYSIS Advises Life Science Innovators. Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK.